These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17324333)

  • 1. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.
    Manochakian R; Miller KC; Chanan-Khan AA
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):266-71. PubMed ID: 17324333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
    Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
    [No Abstract]   [Full Text] [Related]  

  • 5. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
    Biehn SE; Moore DT; Voorhees PM; Garcia RA; Lehman MJ; Dees EC; Orlowski RZ
    Ann Hematol; 2007 Mar; 86(3):211-6. PubMed ID: 17146676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
    Bladé J; Sonneveld P; San Miguel JF; Sutherland HJ; Hajek R; Nagler A; Spencer A; Robak T; Cibeira MT; Zhuang SH; Harousseau JL; Orlowski RZ;
    Clin Lymphoma Myeloma; 2008 Dec; 8(6):352-5. PubMed ID: 19064400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
    Bladé J; Sonneveld P; San Miguel JF; Sutherland HJ; Hajek R; Nagler A; Spencer A; Robak T; Lantz KC; Zhuang SH; Harousseau JL; Orlowski RZ;
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):44-9. PubMed ID: 21454189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
    Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
    Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
    Dytfeld D; Rosebeck S; Kandarpa M; Mayampurath A; Mellacheruvu D; Alonge MM; Ngoka L; Jasielec J; Richardson PG; Volchenboum S; Nesvizhskii AI; Sreekumar A; Jakubowiak AJ
    Br J Haematol; 2015 Jul; 170(1):66-79. PubMed ID: 25824111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
    Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA
    Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of novel combinations for induction therapy in multiple myeloma.
    Voorhees PM; Orlowski RZ
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):33-41. PubMed ID: 16879768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
    Chanan-Khan A; Miller KC; Musial L; Padmanabhan S; Yu J; Ailawadhi S; Sher T; Mohr A; Bernstein ZP; Barcos M; Patel M; Iancu D; Lee K; Czuczman MS
    Leuk Lymphoma; 2009 Jul; 50(7):1096-101. PubMed ID: 19479618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
    Jakubowiak AJ; Kendall T; Al-Zoubi A; Khaled Y; Mineishi S; Ahmed A; Campagnaro E; Brozo C; Braun T; Talpaz M; Kaminski MS
    J Clin Oncol; 2009 Oct; 27(30):5015-22. PubMed ID: 19738129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience.
    Chanan-Khan AA; Lee K
    Clin Lymphoma Myeloma; 2007 Apr; 7 Suppl 4():S163-9. PubMed ID: 17562255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed complete remission in a patient with multiple myeloma.
    Ria R; Vacca A; Mangialardi G; Dammacco F
    Eur J Clin Invest; 2008 Dec; 38(12):966-8. PubMed ID: 19021723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
    Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
    Ning YM; He K; Dagher R; Sridhara R; Farrell AT; Justice R; Pazdur R
    Oncology (Williston Park); 2007 Nov; 21(12):1503-8; discussion 1511, 1513, 1516 passim. PubMed ID: 18077994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.
    Gozzetti A; Fabbri A; Oliva S; Marchini E; Bocchia M; Defina M; Lauria F
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):68-72. PubMed ID: 20223732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.